William Blair Reinstates Outperform on Jasper Therapeutics

William Blair analyst Matt Phipps has reinstated an 'Outperform' rating on Jasper Therapeutics (NASDAQ: JSPR). This action indicates a positive outlook for the company's stock performance in the market.